Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

EndocrineNET

Neuroendocrine Tumors

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06378047 2026-02-09

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Phase 1 Completed

2 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02999477 2026-01-29

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Phase 1 Completed

32 enrolled 23 charts

Breast

Breast Neoplasms

NCT03978689 2026-01-22

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

80 enrolled

Head & Neck

Head and Neck Neoplasms

NCT02856425 2026-01-20

PEMBIB

Phase 1 Completed

196 enrolled

Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT02621398 2025-12-16

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Phase 1 Completed

23 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05165433 2025-12-16

FORTIFY

Phase 1 Completed

14 enrolled

Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

NCT02512172 2025-12-03

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Phase 1 Completed

27 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03486301 2025-11-12

EIK1001

Phase 1 Completed

87 enrolled

Tumor-Agnostic

Neoplasms

NCT04840394 2025-11-12

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

1 enrolled

Tumor-Agnostic

Neoplasms

NCT04374877 2025-11-10

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Phase 1 Completed

145 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT03396445 2025-11-05

MK-5890-001

Phase 1 Completed

182 enrolled 36 charts

BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04323202 2025-10-24

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Phase 1 Completed

13 enrolled

DermatologicHead & Neck

Basal Cell Carcinoma of the Head and Neck

NCT05082610 2025-10-16

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Phase 1 Completed

48 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT05514444 2025-10-09

MK-4464-001

Phase 1 Completed

64 enrolled

Tumor-Agnostic

Neoplasms

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

Phase 1 Completed

59 enrolled 9 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

470 enrolled

Tumor-Agnostic

Neoplasms

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

CNS

Brain Neoplasms, Glioblastoma

NCT05501821 2025-09-25

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

NCT04344795 2025-09-12

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Phase 1 Completed

89 enrolled

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms

NCT05826275 2025-09-09

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

Phase 1 Completed

28 enrolled

HPV Associated Cancers

NCT04879849 2025-09-04

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Phase 1 Completed

34 enrolled 28 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Phase 1 Completed

146 enrolled 38 charts

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT05585034 2025-08-07

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1 Completed

60 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Phase 1 Completed

260 enrolled 52 charts

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT02013154 2025-08-03

P102

Phase 1 Completed

151 enrolled

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT02628574 2025-08-03

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

Phase 1 Completed

109 enrolled

Neoplasm Metastasis, Recurrence

NCT03013218 2025-08-01

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Phase 1 Completed

174 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04153565 2025-07-17

MK-3475-A17

Phase 1 Completed

19 enrolled 14 charts

Other solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Mesothelioma

NCT04937153 2025-07-16

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Phase 1 Completed

18 enrolled

Other solid neoplasm

Solid Tumor

NCT02680184 2025-07-04

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Phase 1 Completed

199 enrolled

Dermatologic

Melanoma

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

Clinical Trials

MK-3475A-C18

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

PEAR

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Phase Ib of L-NMMA and Pembrolizumab

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

Study of DF6215 in Patients With Advanced Solid Tumors

MK-4700-001

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

PEMBIB

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

FORTIFY

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

EIK1001

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

MK-5890-001

MK-1454-001

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

KEYVIBE-001

MK-4464-001

Pembrolizumab in Combination With CRT for LA-SCCHN

MK-4830-001

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

P102

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

MK-3475-A17

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers